Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Efficacy and Safety of Telitacicept in IgAN — Stella

Home/IgA Nephropathy (IgAN)/Efficacy and Safety of Telitacicept in IgAN

View on ClinicalTrials.gov

Recruiting

Back to IgA Nephropathy (IgAN) trials

Efficacy and Safety of Telitacicept in IgAN

Not a traditional drug trial — this study doesn't follow the standard phase structure.

Trial locations(1 site)

China

Ruijin Hospital, Shanghai

Key details

Sponsor

Ruijin Hospital

Collaborators

Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, RenJi Hospital

Enrollment target

~118 participants

Started

December 2024

Primary completion

December 2026

Age range

18 Years – 70 Years

Last updated January 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.